Expression of the Stem Cell Marker CD133 (Prominin-1) in Eccrine and Apocrine Skin Tumors.
Enrique Poblet, Syong H Nam-Cha, Rosario Serrano, Raul Calero, Luis Alfaro. Hospital General Universitario de Albacete, Albacete, Spain; Hospital General Universitario de Albacete, Spain; Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
Background: Human CD133 (human prominin-1) is expressed by various stem and progenitor cells, and has been detected in a small population of neoplastic cells. We describe the CD133 immunohistochemical expression of eccrine and appocrine tumors of the skin.
Design: For immunohistochermical study, a retrospective search retrieved 38 previously diagnosed skin eccrine and apocrine adnexal tumors from the files of the Department of Pathology of the University Hospital Complex of Albacete. All cases were reviewed, and adnexal skin tumors were diagnosed according to the criteria of the WHO classification, including: Eccrine spiradenoma (n=3), Nodular hidradenoma (n=5), Eccrine hidrocystoma (n=3), Poroma (n=5), Porocarcinoma (n=1), Syringocystoadenoma papilliferum (n=3), Chondroid syringoma (n=4), Syringoma (n=6), Cilindroma (n=2), Hidradenoma papilliferum (n=2), apocrine hidrocystoma (n=3) and apocrine carcinoma (n=1). Other types of skin epithelial tumors (5 basal cell carcinomas, and 5 squamous cell carcinomas) were also included in this study to compare the results obtained with those obtained in sweat gland tumors. Slides were treated with heat-induced epitope retrieval and immunostained with three different anti CD133 monoclonal antibodies: the AC133 monoclonal antibody (Miltenyi Biotec, Germany), the W6B3C1 o 292C3 monoclonal antibody (Miltenyi Biotec, Germany), and the AC141 monoclonal antibody (Miltenyi Biotec, Germany). CD133 detection was performed by using the EnVision system-HRP (Dako, Glostrup, Denmark) in the DakoCytomation Autostainer platform.
Results: CD133 was not expressed in any of the basal cell carcinomas and squamous cell carcinomas tested. The overall immunohstochemical staining pattern observed in the studied adnexal tumors was closely related to tissue architecture, being positive in the ductal or acinar areas of the eccrine tumors. CD133 immunoreactivity was mainly seen in the apical/endoluminal surface of duct-like structures or cysts of all the benign and malignant eccrine tumors.
Conclusions: Our findings demonstrate that CD133 protein is not restricted to stem cells. CD133 is widely expressed on differentiated luminal and ductal epithelial cells of different eccrine skin adnexal tumors.
Wednesday, March 2, 2011 1:00 PM
Poster Session VI # 118, Wednesday Afternoon